Navigation Links
Clontech Laboratories, Inc. Releases the Xfect(TM) and Xfect(TM) Stem Transfection Reagents
Date:5/28/2009

Bio Inc., develops, manufactures, and distributes a wide range of life science research reagents under the Clontech and Takara brands. Key products include high-performance qPCR and PCR reagents (including the Ex Taq(TM), LA Taq(TM), Titanium(TM), and Advantage(R) enzymes); RT enzymes and SMART(TM) library construction kits; the innovative In-Fusion(TM) cloning system; Tet-based inducible gene expression systems; and a range of Macherey-Nagel nucleic acid purification tools. These and other products support applications including gene discovery, regulation, and function; protein expression and purification; RNAi and stem cell studies; and plant and food research. For more information visit www.clontech.com.

About Takara Bio Inc.

Takara Bio Inc. is an innovative biotechnology company based in Shiga, Japan. As a world leader in biotechnology research and development, Takara Bio was the first company to market PCR technology in Japan and is also the developer of the RetroNectin(R) reagent, which is a world-standard in gene therapy protocols. In addition to providing research reagents and equipment to the life science research market, Takara Bio has active research and product development activities in the fields of gene and cell-based therapy, and agricultural biotechnology; and is committed to preventing disease and improving the quality of life for all people through the use of biotechnology. Through strategic alliances with other industry leaders, the Company aims to extend its reach around the world. More information is available at http://www.takara-bio.com.


'/>"/>
SOURCE Clontech Laboratories, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Clontech Laboratories, Inc. Releases the ProteoTuner(TM) Systems
2. Clontech Laboratories, Inc. Recognizes the 2008 Winners of the Nobel Prize in Chemistry
3. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Methimazole Tablets USP, 5 mg and 10 mg
4. Forest Laboratories, Inc. and Merz Pharma GmbH & Co. KgaA File Additional Lawsuit Against Several Companies for Patent Infringement
5. Forest Laboratories, Inc. Announces Positive Results of Memantine Study of Once-Daily Formulation
6. Forest Laboratories, Inc. Announces Amendment to Bystolic(TM) (nebivolol) Agreement
7. Forest Laboratories, Inc. and Daiichi Sankyo, Inc. Announce the Termination of the AZOR Co-Promotion Agreement
8. Forest Laboratories, Inc. and Laboratorios Almirall, S.A. to Host Webcast to Discuss Aclidinium Bromide Data Presentations at the American Thoracic Society Annual Congress
9. Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2009 First Quarter Earnings
10. Caraco Pharmaceutical Laboratories, Ltd. Announces Resignation from Board of Directors of Jitendra Doshi and Appointment of GP Singh Sachdeva
11. Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the First Quarter of Fiscal Year 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... 2015 Global Stem Cells ... with Shenzhen HANK Bioengineering Co., Ltd. and its ... will establish a stem cells training course in ... September 2015. , Shenzhen HANK is a biotechnology ... scientist, microbiologist and virologist, to integrate research, development, ...
(Date:2/28/2015)... Increasing its efforts to resolve the ... three episodes of The GMO TRUTH podcast on both ITunes ... it continues its mission to discover the truth and change ... to “uncover the truth about the GMOs in our food ... Truth Podcast is an expansion of the documentary/investigative film-making methodology ...
(Date:2/27/2015)... Calif. , Feb. 27, 2015  Pharmacyclics, ... that longer-term toxicology studies for its newly developed ... or RA, have been completed. The results of ... U.S. Food and Drug Administration. The feedback received ... of the ongoing first-in-human study. Additional preclinical work ...
(Date:2/27/2015)... Nova Scotia (PRWEB) February 27, 2015 ... stage vaccine and immunotherapy company, today announced that ... its application for Fast Track designation and Phase ... vaccines, in conjunction with the mutual co-development agreement ... previously obtained Fast Track designation for the DPX-Survivac. ...
Breaking Biology Technology:Global Stem Cells Group Announces Alliance with HANK Bioengineering Co., Ltd. in Shenzhen, China 2Global Stem Cells Group Announces Alliance with HANK Bioengineering Co., Ltd. in Shenzhen, China 3The Walk a Mile Project Launches “GMO Truth” Podcast 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 3Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3
... , ... assay • LEADseeker • SPA Imaging Beads, ... present in high levels in the pituitary and are processed into ... and β-endorphin. The various melanocyte stimulating hormones are known to activate ...
... , ... kinase assay • LEADseeker • chemiluminescence , , ... least 500 kinase and phosphatase enzymes exist, their activities having ... cascade in disease pathways such as inflammation and cancer, so ...
... , ... workspace • base set • differential expression analysis • principal components ... , ... advanced statistics on samples from a study on human ovarian cancer. ...
Cached Biology Technology:The development of a melanocortin MC4 receptor binding assay using the LEADseeker Multimodality Imaging System 2The development of a melanocortin MC4 receptor binding assay using the LEADseeker Multimodality Imaging System 3The development of a melanocortin MC4 receptor binding assay using the LEADseeker Multimodality Imaging System 4The development of a melanocortin MC4 receptor binding assay using the LEADseeker Multimodality Imaging System 5Performance of the AMARA HitHunter Chemiluminescence Kinase Assay with the LEADseeker Multimodality Imaging System 2Performance of the AMARA HitHunter Chemiluminescence Kinase Assay with the LEADseeker Multimodality Imaging System 3Performance of the AMARA HitHunter Chemiluminescence Kinase Assay with the LEADseeker Multimodality Imaging System 4Extended data analysis using DeCyder EDA 2Extended data analysis using DeCyder EDA 3Extended data analysis using DeCyder EDA 4Extended data analysis using DeCyder EDA 5Extended data analysis using DeCyder EDA 6Extended data analysis using DeCyder EDA 7Extended data analysis using DeCyder EDA 8Extended data analysis using DeCyder EDA 9Extended data analysis using DeCyder EDA 10
(Date:2/23/2015)... Feb. 23, 2015 NXT-ID, Inc. (NASDAQ: ... a biometric authentication company focused on the growing mobile ... patent 62114357 for DISTRIBUTED VOICE DIRECTED PAYMENT ... introduces a new groundbreaking payment method. Payment accounts may ... may only be accessed if both the speech (the ...
(Date:2/18/2015)... , Feb. 18, 2015  Cepheid (NASDAQ: ... at the following conferences, and invited investors to participate via ... Boston, MA Tuesday, March 3, 2015 at ... Conference, Orlando, FL Wednesday, March 4, ... Webcasts To access the live webcasts for these events, please ...
(Date:2/12/2015)... , Feb. 12, 2015   MedNet ... specializing in clinical study management systems, has recently ... , further distinguishing iMedNet ... Research Organizations (CROs) and healthcare consultants.  Building on ... prospective customer referrals and numerous co-marketing opportunities), MedNet,s ...
Breaking Biology News(10 mins):NXT-ID Patents Voice Directed Payments 2NXT-ID Patents Voice Directed Payments 3Cepheid to Webcast Upcoming Financial Presentations 2MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2
... /PRNewswire-iReach/ -- Over the past several weeks and months there ... sites that discuss Pro Ana in any form or that ... like that promote dangerous conditions such as anorexia and bulimia, ... ) The premise is that they encourage, support ...
... YORK, JULY 10, 2013 Researchers at Memorial ... have developed a new method for identifying the ... within multicellular environments. The technique, named ... (CTAP), exploits the inability of vertebrate cells to ...
... depleting the Earth,s supply of oil are unwarranted, according to ... as opposed to the supply will reach its own ... painted pictures of everything from a calm development of alternatives ... world reaches its peak of oil production and then ...
Cached Biology News:Pro Ana and Thinspiration Sites Under Attack 2Pro Ana and Thinspiration Sites Under Attack 3Stanford researchers say 'peak oil' concerns should ease 2Stanford researchers say 'peak oil' concerns should ease 3
... between P-selectin and P-selectin glycoprotein ligand-1 (PSGL-1) ... the lumenal surface of endothelial cells at ... primary role of PSGL-1 in mediating the ... well documented.MAB4092 completely blocks recognition of PSGL-1 ...
Request Info...
... Printing Kit contains choice of Printing Surface (3 glass ... Ti adhesion layer, 1 silicon wafer coated with 1000 ... plain glass slides) and PDMS Stamps (3 PDMS micropatterned ... or 100 um x 10 mm or 200 um ...
LTBP-1 (E-20)...
Biology Products: